Literature DB >> 2841960

Lisinopril: dose-peak effect relationship in essential hypertension.

V J Cirillo1, H J Gomez, J Salonen, R Salonen, V Rissanen, J A Bolognese, R Nyberg, K Kristianson.   

Abstract

1. The dose-peak effect relationship of lisinopril was evaluated in a double-blind, parallel study in 83 patients with mild to moderate essential hypertension (supine diastolic blood pressure = 95-115 mm Hg). 2. After a 4 week placebo washout, patients were randomly assigned to one of four treatments: lisinopril 2.5, 10, 20 or 80 mg day-1 for 1 week. 3. Lisinopril 10 and 20 mg day-1 produced similar peak antihypertensive effects which were greater than that produced by 2.5 mg day-1, but less than that of 80 mg day-1. If the incidence of first-dose symptomatic hypotension is related to the peak effect, then an initial lisinopril dose of 20 mg should not pose any greater risk than a 10 mg dose. 4. The magnitude of antihypertensive response at 24 h postdrug appeared to be dose related across the 2.5 to 80 mg day-1 range.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2841960      PMCID: PMC1386425          DOI: 10.1111/j.1365-2125.1988.tb03342.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  16 in total

1.  Controlled multicenter study of the antihypertensive effects of lisinopril, hydrochlorothiazide, and lisinopril plus hydrochlorothiazide in the treatment of 394 patients with mild to moderate essential hypertension.

Authors:  J L Pool; J Gennari; R Goldstein; M S Kochar; A J Lewin; M H Maxwell; J A McChesney; J Mehta; D T Nash; E B Nelson
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

2.  The antihypertensive effect of lisinopril compared to atenolol in patients with mild to moderate hypertension.

Authors:  K Bolzano; J Arriaga; R Bernal; H Bernardes; J L Calderon; J Debruyn; F Dienstl; J Drayer; T L Goodfriend; W Gross
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

3.  Long-term monotherapy with lisinopril in renovascular hypertension.

Authors:  F Fyhrquist; C Grönhagen-Riska; I Tikkanen; I L Junggren
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

Review 4.  The clinical pharmacology of lisinopril.

Authors:  H J Gomez; V J Cirillo; F Moncloa
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

5.  Evaluation of antihypertensive efficacy of lisinopril compared to metoprolol in moderate to severe hypertension.

Authors:  P K Zachariah; G Bonnet; S G Chrysant; G DeBacker; R Goldstein; J Herrera; A Lindner; B J Materson; M H Maxwell; F G McMahon
Journal:  J Cardiovasc Pharmacol       Date:  1987       Impact factor: 3.105

6.  Captopril-induced functional renal insufficiency in patients with bilateral renal-artery stenoses or renal-artery stenosis in a solitary kidney.

Authors:  D E Hricik; P J Browning; R Kopelman; W E Goorno; N E Madias; V J Dzau
Journal:  N Engl J Med       Date:  1983-02-17       Impact factor: 91.245

7.  Relation between serum sodium concentration and the hemodynamic and clinical responses to converting enzyme inhibition with captopril in severe heart failure.

Authors:  M Packer; N Medina; M Yushak
Journal:  J Am Coll Cardiol       Date:  1984-04       Impact factor: 24.094

8.  Antihypertensive effect of single doses of enalapril in hypertensive patients treated with bendrofluazide.

Authors:  J Webster; D Newnham; O J Robb; J C Petrie
Journal:  Br J Clin Pharmacol       Date:  1987-02       Impact factor: 4.335

9.  Angiotensin II levels, hemodynamics, and sympathoadrenal function after low-dose captopril in heart failure.

Authors:  J Cleland; P Semple; P Hodsman; S Ball; I Ford; H Dargie
Journal:  Am J Med       Date:  1984-11       Impact factor: 4.965

10.  Severe hypotension after first dose of enalapril in heart failure.

Authors:  J G Cleland; H J Dargie; H McAlpine; S G Ball; J J Morton; J I Robertson; I Ford
Journal:  Br Med J (Clin Res Ed)       Date:  1985-11-09
View more
  4 in total

Review 1.  Angiotensin converting enzyme inhibitors and moderate hypertension.

Authors:  D McAreavey; J I Robertson
Journal:  Drugs       Date:  1990-09       Impact factor: 9.546

2.  Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial.

Authors:  K J Schjoedt; A S Astrup; F Persson; E Frandsen; F Boomsma; K Rossing; L Tarnow; P Rossing; H-H Parving
Journal:  Diabetologia       Date:  2008-10-31       Impact factor: 10.122

3.  A comparison of the effect of lisinopril and hydrochlorothiazide on electrolyte balance in essential hypertension.

Authors:  D B Frewin; R C Bartholomeusz; R D Gaffney; A D Clampett; B E Chatterton
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

Review 4.  Choosing the right ACE inhibitor. A guide to selection.

Authors:  G Leonetti; C Cuspidi
Journal:  Drugs       Date:  1995-04       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.